Correction to: ACG Clinical Guideline: Management of Crohn’s Disease in Adults (The American Journal of Gastroenterology, (2018), 113, 4, (481-517), 10.1038/ajg.2018.27)

Gary R. Lichtenstein, Edward V. Loftus, Kim L. Isaacs, Miguel D. Regueiro, Lauren B. Gerson, Bruce E. Sands

Research output: Contribution to journalComment/debatepeer-review

7 Scopus citations

Abstract

Since the publication of these Guidelines, the authors have noticed an error in the text on page 15. The incorrect statement is: Since the publication of these Guidelines, the authors have noticed an error in the text on page 15. The incorrect statement is: A recent guideline has suggested minimal “therapeutic” target trough levels; infliximab ≥7.5 μg/ml, adalimumab ≥5 μg/ml, and certolizumab pegol ≥20 μg/ml (161). The corrected statement is as follows: A recent guideline has suggested minimal “therapeutic” target trough levels; infliximab ≥5 μg/ml, adalimumab ≥7.5 μg/ml, and certolizumab pegol ≥20 μg/ml (161).

Original languageEnglish (US)
Number of pages1
JournalAmerican Journal of Gastroenterology
Volume113
Issue number7
DOIs
StatePublished - Jul 1 2018

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Correction to: ACG Clinical Guideline: Management of Crohn’s Disease in Adults (The American Journal of Gastroenterology, (2018), 113, 4, (481-517), 10.1038/ajg.2018.27)'. Together they form a unique fingerprint.

Cite this